The DANTE trial protocol: a randomised phase III trial to evaluate the Duration of ANti-PD-1 monoclonal antibody Treatment in patients with metastatic mElanoma

Coen, O., Corrie, P., Marshall, H. et al. (17 more authors) (2021) The DANTE trial protocol: a randomised phase III trial to evaluate the Duration of ANti-PD-1 monoclonal antibody Treatment in patients with metastatic mElanoma. BMC Cancer, 21 (1). 761. ISSN 1471-2407

Abstract

Metadata

Authors/Creators:
  • Coen, O.
  • Corrie, P.
  • Marshall, H.
  • Plummer, R.
  • Ottensmeier, C.
  • Hook, J.
  • Bell, S.
  • Sagoo, G.S.
  • Meads, D.
  • Bestall, J.
  • Velikova, G.
  • Gallagher, F.A.
  • Smith, A.
  • Howard, H.
  • Mason, E.
  • Katona, E.
  • Silva, S.
  • Collinson, M.
  • Rodwell, S.
  • Danson, S. ORCID logo https://orcid.org/0000-0002-3593-2890
Copyright, Publisher and Additional Information: © The Author(s). 2021. Open Access: This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Keywords: Immunotherapy; Checkpoint inhibitor; Anti-PD-1; Metastatic melanoma; Schedule; Efficacy; Safety; Quality of life
Dates:
  • Accepted: 14 June 2021
  • Published (online): 1 July 2021
  • Published: 1 July 2021
Institution: The University of Sheffield
Academic Units: The University of Sheffield > Sheffield Teaching Hospitals
Funding Information:
FunderGrant number
NIHR Evaluation Trials and Studies Coordinating CentreNIHRDH-HTA/15/57/66
Depositing User: Symplectic Sheffield
Date Deposited: 20 Jul 2021 11:08
Last Modified: 22 Jul 2021 04:50
Status: Published
Publisher: Springer Science and Business Media LLC
Refereed: Yes
Identification Number: https://doi.org/10.1186/s12885-021-08509-w
Related URLs:

Share / Export

Statistics